CUE BIOPHARM.INC. DL-,001 Forum: Community User: Support

Ja ist mir Schonmal woanders aufgefallen

Wie ist eure Vermutung für Kursentwicklung Montag ?

Kann man null einschätzen am Dienstag stand die Aktie bei 16 Cent und gestern im hoch ja schon mehr als verdoppelt

Wie sind eure EK wenn ich fragen darf? Meiner liegt bei 0,39€ mittlerweile

7000 Anteile Ek 16,6 Cent

Ok also Montag. Dann schaun mer mal wie der Kurs sich im pre bewegen wird

In der Meldung von reuters steht wohl drinnen das am 13 April über einen Reverse Split abgestimmt wird

Hui bei L&S bewegt sich hier heute sogar was

Based on the available information up to April 2026, there is no official announcement regarding a reverse stock split (RS) vote for Cue Biopharma (CUE). Instead, recent activity indicates the company has been navigating a low stock price through other means: Recent Public Offering: On September 26, 2024, Cue Biopharma announced a $12 million public offering at $0.50 per share. Strategic Focus: The company has been focusing on its autoimmune pipeline (CUE-401) and has reported significant collaboration revenue from partnerships, such as with ImmunoScape in late 2025. Stock Performance: The stock has experienced significant volatility and has traded at very low levels, frequently nearing 52-week lows, which sometimes prompts speculation about reverse splits to maintain NASDAQ listing compliance. However, a specific vote on this measure is not in the recent news

Jupp, naja Montag hoffentlich wieder grün

Ah sieht bitter aus

Die KI findet auch nichts: As of April 2026, there is no record of a stock split or reverse split (resplit) for Cue Biopharma (CUE). The company, which is focused on immunotherapy, recently reported a $7.5 million milestone payment from a partnership with Boehringer Ingelheim. Stock Split History: According to Seeking Alpha, Cue Biopharma has not executed any stock splits, including reverse splits. Recent News: In April 2026, Cue Biopharma announced it would receive a $7.5 million preclinical milestone payment from Boehringer Ingelheim as part of their collaborative agreement. Financials: Yahoo Finance shows a recent quarterly earnings beat, but the company has faced a challenging small-cap environment

Bin die SEC Filings nochmal durchgegangen gerade aber da war nichts bezüglich Resplit

Schaun mer mal wo wir am Montag starten werden

Bei mir gleich hatte ich gestern auch geschaut aber man konnte nichts finden aber wer weiß